AR116663A1 - Compuestos - Google Patents

Compuestos

Info

Publication number
AR116663A1
AR116663A1 ARP190101764A ARP190101764A AR116663A1 AR 116663 A1 AR116663 A1 AR 116663A1 AR P190101764 A ARP190101764 A AR P190101764A AR P190101764 A ARP190101764 A AR P190101764A AR 116663 A1 AR116663 A1 AR 116663A1
Authority
AR
Argentina
Prior art keywords
formula
compounds
hydrogen
treatment
methods
Prior art date
Application number
ARP190101764A
Other languages
English (en)
Spanish (es)
Inventor
Scott Coleman
Roy Lester
Dean Rivers
Esther Duperchy
Steven Boakes
Mona Simonovic
Michael Dawson
Pamela Brown
Original Assignee
Spero Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Spero Therapeutics Inc filed Critical Spero Therapeutics Inc
Publication of AR116663A1 publication Critical patent/AR116663A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50—Cyclic peptides containing at least one abnormal peptide link
    • C07K7/54—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
    • C07K7/60—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring the cyclisation occurring through the 4-amino group of 2,4-diamino-butanoic acid
    • C07K7/62—Polymyxins; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
ARP190101764A 2018-06-25 2019-06-25 Compuestos AR116663A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201862689602P 2018-06-25 2018-06-25

Publications (1)

Publication Number Publication Date
AR116663A1 true AR116663A1 (es) 2021-06-02

Family

ID=67107423

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP190101764A AR116663A1 (es) 2018-06-25 2019-06-25 Compuestos

Country Status (31)

Country Link
US (3) US11459357B2 (enExample)
EP (2) EP3810633B1 (enExample)
JP (2) JP7488774B2 (enExample)
KR (1) KR20210054500A (enExample)
CN (2) CN118878638A (enExample)
AR (1) AR116663A1 (enExample)
AU (2) AU2019294261B2 (enExample)
BR (1) BR112020026663A2 (enExample)
CA (1) CA3103158A1 (enExample)
CO (1) CO2020016080A2 (enExample)
DK (1) DK3810633T3 (enExample)
EA (1) EA202092819A1 (enExample)
ES (1) ES2971732T3 (enExample)
FI (1) FI3810633T3 (enExample)
HR (1) HRP20240028T1 (enExample)
HU (1) HUE065134T2 (enExample)
IL (2) IL279620B2 (enExample)
LT (1) LT3810633T (enExample)
MA (1) MA52946B1 (enExample)
MD (1) MD3810633T2 (enExample)
MX (1) MX2020013811A (enExample)
PH (1) PH12020552240A1 (enExample)
PL (1) PL3810633T3 (enExample)
PT (1) PT3810633T (enExample)
RS (1) RS65128B1 (enExample)
SG (1) SG11202012747VA (enExample)
SI (1) SI3810633T1 (enExample)
TW (2) TWI851584B (enExample)
UA (1) UA128162C2 (enExample)
WO (1) WO2020002325A1 (enExample)
ZA (1) ZA202301937B (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107108699A (zh) 2014-11-26 2017-08-29 新药物许可控股有限公司 化合物
DK3810633T3 (da) * 2018-06-25 2024-01-15 Spero Therapeutics Inc Forbindelser
TW202233649A (zh) 2020-11-06 2022-09-01 美商斯佩羅治療學股份有限公司 化合物
WO2022262823A1 (zh) * 2021-06-18 2022-12-22 华南理工大学 活性氧自由基响应的多粘菌素前药化合物及其应用
CN120574287B (zh) * 2025-06-10 2026-07-03 中国药科大学 一种抗菌肽、组合物及应用
CN121159640A (zh) * 2025-07-24 2025-12-19 中国药科大学 一种抗菌肽、药物组合物及应用
CN120699105B (zh) * 2025-08-19 2025-11-21 中国药科大学 一种氘代抗菌肽及其组合物和应用

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2128617A (en) 1982-10-06 1984-05-02 Martti Vaara Polypeptides for use in antibacterial therapy
AU7753787A (en) 1986-08-06 1988-02-24 Jean-Luc Fauchere Production of covalent-linked conjugates from an antibiotic and a non-toxic derivative of polymyxine b
US20010021697A1 (en) 1987-09-14 2001-09-13 Henning Lowenstein Methods and compositions for the treatment of mammalian infections employing medicaments comprising hymenoptera venom, proteinageous or polypeptide components thereof, or analogues of such proteinaceous or polypeptide components
TW274552B (enExample) 1992-05-26 1996-04-21 Hoechst Ag
US5767068A (en) 1997-02-13 1998-06-16 Pathogenesis Corporation Pure biologically active colistin, its components and a colistin formulation for treatment of pulmonary infections
JP2007507512A (ja) 2003-09-30 2007-03-29 コーヒ コーポレーション 熱傷を治療するための組成物および方法
US20060004185A1 (en) 2004-07-01 2006-01-05 Leese Richard A Peptide antibiotics and peptide intermediates for their prepartion
BRPI0715095B8 (pt) 2006-08-11 2021-05-25 Northern Antibiotics Oy derivado de polimixina da fórmula geral (i); produto de combinação; composição farmacêutica; método para se sensibilizar bactérias gram-negativas a um agente antibacteriano; método para o desenvolvimento de antibióticos; método para a redução da toxicidade de polimixinas, octapeptinas naturais e seus derivados durante a aplicação das mesmas no tratamento de infecções em um indivíduo; método para melhorar as propriedades farmacocinéticas, de polimixinas, octapeptinas naturais e seus derivados; método para a sensibilização de bactérias gram-negativas clinicamente importantes a um complemento de mecanismo de defesa presente no soro; uso de um derivado; e processo para a preparação de um derivado de polimixina da fórmula (i).
US7807637B2 (en) 2006-08-11 2010-10-05 Northern Antibiotics Oy Polymyxin derivatives and uses thereof
US8329645B2 (en) 2008-02-08 2012-12-11 Northern Antibiotics Ltd. Polymyxin derivatives and uses thereof
US8193148B2 (en) 2008-02-08 2012-06-05 Northern Antibiotics Ltd. Short fatty acid tail polymyxin derivatives and uses thereof
FI20085469A0 (fi) 2008-02-08 2008-05-16 Northern Antibiotics Oy Polymyksiinijohdannaiset, joissa on lyhyt rasvahappohäntä, ja niiden käyttöjä
ES2334547B1 (es) 2008-09-10 2010-12-03 Universidad De Barcelona Compuestos peptidicos antibacterianos.
WO2010075416A1 (en) 2008-12-23 2010-07-01 Biosource Pharm, Inc. Antibiotic compositions for the treatment of gram negative infections
CN101851270A (zh) 2009-04-03 2010-10-06 梁浩 一种多粘菌素衍生物及其制备方法
WO2010130007A1 (en) 2009-05-14 2010-11-18 Monash University Antimicrobial compounds
US8415307B1 (en) 2010-06-23 2013-04-09 Biosource Pharm, Inc. Antibiotic compositions for the treatment of gram negative infections
WO2012051663A1 (en) 2010-10-21 2012-04-26 Monash University Antimicrobial compounds
WO2012168820A1 (en) * 2011-06-08 2012-12-13 Pfizer Inc. Polymyxin derivatives useful as antibacterial agents
MX355217B (es) 2011-11-18 2018-04-10 New Pharma Licence Holdings Ltd Derivados de polimixina.
HUE059544T2 (hu) 2013-05-22 2022-11-28 Spero Therapeutics Inc Polimixin-származékok és ezek alkalmazása kombinációs terápiában különbözõ antibiotikumokkal
KR20160135739A (ko) * 2014-03-11 2016-11-28 뉴 파마 라이센스 홀딩스 리미티드 폴리믹신 유도체 및 상이한 항생제와의 조합 요법에 있어서의 이들의 용도
US10047126B2 (en) 2014-04-01 2018-08-14 Monash University Polymyxin derivatives as antimicrobial compounds
CN107108699A (zh) 2014-11-26 2017-08-29 新药物许可控股有限公司 化合物
BR112017010888A2 (pt) * 2014-12-17 2018-02-27 Hoffmann La Roche método para produzir um produto de conjugação enzimática de três polipeptídeos
WO2016166103A1 (en) * 2015-04-13 2016-10-20 Xellia Pharmaceuticals Aps Polymyxin derivatives
JP7367950B2 (ja) * 2015-09-29 2023-10-24 モナッシュ ユニバーシティ 抗菌性ポリミキシン誘導体化合物
US10428122B2 (en) * 2016-06-16 2019-10-01 International Aids Vaccine Initiative, Inc. Tuberculosis compositions and methods of treating or preventing tuberculosis
DK3810633T3 (da) * 2018-06-25 2024-01-15 Spero Therapeutics Inc Forbindelser
WO2020014501A1 (en) 2018-07-11 2020-01-16 Cidara Therapeutics, Inc. Compositions and methods for the treatment of bacterial infections

Also Published As

Publication number Publication date
CN118878638A (zh) 2024-11-01
MA52946A (fr) 2021-04-28
IL279620B1 (en) 2025-11-01
RS65128B1 (sr) 2024-02-29
WO2020002325A1 (en) 2020-01-02
US20230012121A1 (en) 2023-01-12
EA202092819A1 (ru) 2021-05-21
MX2020013811A (es) 2021-03-09
NZ771833A (en) 2024-09-27
JP2021528449A (ja) 2021-10-21
MD3810633T2 (ro) 2024-05-31
CA3103158A1 (en) 2020-01-02
HRP20240028T1 (hr) 2024-03-29
IL279620B2 (en) 2026-03-01
TWI851584B (zh) 2024-08-11
LT3810633T (lt) 2024-01-10
EP4316504A2 (en) 2024-02-07
IL323560A (en) 2025-11-01
US20260103491A1 (en) 2026-04-16
BR112020026663A2 (pt) 2021-03-23
CN112789287B (zh) 2024-06-21
US20210246169A1 (en) 2021-08-12
ZA202301937B (en) 2023-09-27
TW202446783A (zh) 2024-12-01
HUE065134T2 (hu) 2024-05-28
MA52946B1 (fr) 2024-03-29
FI3810633T3 (fi) 2024-02-09
AU2019294261A1 (en) 2021-02-04
SI3810633T1 (sl) 2024-04-30
CO2020016080A2 (es) 2021-01-18
PH12020552240A1 (en) 2021-08-16
EP3810633B1 (en) 2023-12-13
AU2024203362A1 (en) 2024-06-06
JP2024109664A (ja) 2024-08-14
DK3810633T3 (da) 2024-01-15
US11459357B2 (en) 2022-10-04
EP3810633A1 (en) 2021-04-28
ES2971732T3 (es) 2024-06-06
US12528837B2 (en) 2026-01-20
TW202019949A (zh) 2020-06-01
AU2019294261B2 (en) 2024-02-29
PT3810633T (pt) 2024-02-19
EP4316504A3 (en) 2024-04-17
SG11202012747VA (en) 2021-01-28
PL3810633T3 (pl) 2024-04-08
IL279620A (en) 2021-03-01
JP7488774B2 (ja) 2024-05-22
CN112789287A (zh) 2021-05-11
UA128162C2 (uk) 2024-04-24
KR20210054500A (ko) 2021-05-13

Similar Documents

Publication Publication Date Title
CO2020016080A2 (es) Compuestos
CL2020001546A1 (es) Compuestos de 4-azaindol.
AR123048A2 (es) Moduladores de p2x7
ECSP15029636A (es) Nuevos compuestos bicíclicos y su uso como agentes antibacterianos e inhibidores de beta-lactamasa
CO2017009891A2 (es) Inhibidores de inhibidores del factor beta de crecimiento de transformación (tgf-beta)
MX2018004207A (es) Nuevos compuestos de espiro[3h-indol-3,2â´-pirrolidin]-2(1h)-ona y derivados como inhibidores de mdm2-p53.
MX2020007485A (es) Compuestos antiproliferativos y metodos de uso de los mismos.
UY35898A (es) ?compuestos inhibidores de syk y composiciones que los comprenden?.
BR112015023397A2 (pt) benzoxazois substituídos e métodos de uso dos mesmos
BR112015022488A2 (pt) triazolopiridinas substituídas e métodos de uso das mesmas
UY35617A (es) Inhibidores de la fosfatidilinositol 3-quinasa
MX2018012544A (es) Nuevos derivados de pirazolopirimidina.
MX2013006847A (es) Compuesto heterociclico fusionado y su uso para el control de plagas.
ECSP14020586A (es) Composición para el control de plagas que incluye un derivado de iminopiridina novedoso
UY36285A (es) Compuestos que inhiben la proteína mcl-1
AR084553A1 (es) DERIVADOS IMIDAZOLICOS HETEROCICLICOS INHIBIDORES DE b-SECRETASA, COMPOSICIONES FARMACEUTICAS QUE LOS CONTIENEN Y USO DE LOS MISMOS PARA TRATAR ENFERMEDADES NEURODEGENERATIVAS, EN PARTICULAR ALZHEIMER
DOP2019000140A (es) Compuestos de heterociclo tetracíclicos útiles como inhibidores de la integrasa del vih
AR098776A1 (es) Derivados del isocromeno como inhibidores de las fosfoinositido-3 quinasas
MX2013008868A (es) Nuevas azaindolifenil sulfonamidas como inhibidores de serina/treonina cinasa.
CR20170118A (es) Derivados espirodiamina como inhibidores de la aldosterona sintasa
BR112019007108A2 (pt) misturas herbicidas
DOP2022000070A (es) Inhibidor de diacilglicerol aciltransferasa 2
PE20212327A1 (es) Ciertos compuestos de pladienolida y metodos de uso
CO2020004977A2 (es) Compuestos bicíclicos para su uso como inhibidores de la ripi quinasa
DOP2010000022A (es) Derivados de pirimidina 934